T1	Premise 1011 1188	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
T2	Premise 1189 1345	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
T3	Premise 1346 1509	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
T4	Premise 1566 1665	There were no differences in the proportions of patients in the two groups that reported worsening.
T5	Claim 1666 1861	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
R1	Support Arg1:T1 Arg2:T5	
R2	Support Arg1:T2 Arg2:T5	
T6	Premise 1510 1565	but the differences were not statistically significant.
R3	Attack Arg1:T6 Arg2:T3	
